Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
The webcast and replay will be available on the Company’s investor relations website on the page.
About Cybin
Cybin® is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the
Founded in 2019, Cybin is operational in
View source version on businesswire.com:
Investor Contact:
Candice Masse
astr partners
Managing Director
(978) 879-7273
[email protected]
Media Contact:
Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
[email protected] � or � [email protected]
Source: Cybin Inc.
